According to our latest study on " Infectious Disease Therapeutics Market Forecast to 2030 - Global Analysis - Drug Class, Indication, Route of Administration, and Distribution Channel," the infectious disease therapeutics market was valued at US$ 1,19,708.77 million in 2022 and is expected to reach US$ 1,67,883.93 million by 2030. The market is estimated to register a CAGR of 4.3% from 2022 to 2030. The report highlights the key factors and trends impacting the market and focuses on prominent players and their strategies.
Infectious diseases can transfer from one person to another through direct or indirect contact. Patients must take medications with anti-infective properties to treat infectious diseases. Pathogens such as bacteria, fungi, viruses, and parasites are the primary cause of these disorders. To target the organism causing the sickness and implement a remedy, the host's defensive system is directly targeted.
The growing incidence of infectious diseases is anticipated to increase the sales of infectious disease therapeutics drugs in developing countries. Asia Pacific has become an adaptable and business-friendly hub due to moderately fewer data requirements and stringent regulations. In addition, high investments in health research and life science in emerging countries play a key role in promoting the latest technologies in developing countries, which, in turn, supports the inclination toward infectious disease diagnosis and treatment. For instance, UNAIDS is advocating for an investment of US$ 29 billion by 2025 to meet the needs of low- and middle-income countries to prevent and treat AIDS. In India, South Korea, Brazil, and Mexico, there is a high prevalence of infectious diseases such as Hepatitis, HAI, HIV, and influenza; a large population of patients; a rise in disposable income of the population; improved infrastructure of healthcare; and growing medical tourism. Thus, crucial infectious disease therapeutics product manufacturers in emerging infectious disease therapeutics markets in these countries are expected to witness lucrative opportunities in the future.
Pfizer Inc., Gilead Sciences Inc., F. Hoffmann-La Roche Ltd, Shionogi & Co Ltd, Bayer AG, BioCryst Pharmaceuticals Inc., GSK Plc, AbbVie Inc, Merck & Co Inc., and Astellas Pharma Inc are among the key players operating in the global infectious disease therapeutics market.
The report segments the global infectious disease therapeutics market as follows:
The infectious disease therapeutics market is segmented based on drug class, indication, route of administration, and distribution channel. The infectious disease therapeutics market is subsegmented by drug class into anti-viral, anti-bacterial, anti-fungal, and others. Based on indication, the infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. Regarding route of administration, the infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The infectious disease therapeutics market, by distribution channel, is categorized into hospital pharmacies, retail pharmacies, and others. The infectious disease therapeutics market, based on geography, is segmented into North America (US, Canada, and Mexico), Europe (France, Germany, Italy, UK, Spain, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia Pacific), Middle East & Africa (Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, Rest of South & Central America).
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com